Braeburn Access ProgramTM

Welcome to the Braeburn Access ProgramTM. As you are aware, Braeburn Pharmaceuticals developed PROBUPHINE® (buprenorphine) implant for subdermal administration, which is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent). As you identify patients that may benefit from this new therapy for opioid addiction, Braeburn offers a support program to assist you through certification to administer PROBUPHINE®, as well as determining access and affordability options for your patients.

The program offers services that include:

  • Information on the Risk Evaluation and Mitigation Strategy (REMS) program for PROBUPHINE in addition to the requirements and training needed for administration.
  • Easy Program Enrollment Information to assist patient with therapy initiation
  • Coverage, Coding and Reimbursement Support to facilitate complete and accurate claim submission
    • Benefits investigations
    • Prior Authorizations
    • Appeals
  • Direct Product Ordering
    • Patient Orders
    • Replacements
    • Returns

WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL

Risk associated with Insertion and Removal

Insertion and removal of Probuphine are associated with the risk of implant migration, protrusion, expulsion, and nerve damage resulting from the procedure. Serious but rare complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion. All Healthcare Providers must successfully complete a live training program and become certified prior to performing insertion and/or removal of Probuphine implants.

Because of the risks associated with insertion and removal, Probuphine is available only through a restricted program called the Probuphine REMS Program. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing Probuphine implants. Patients must be monitored to ensure that Probuphine is removed by a healthcare provider certified to perform insertions.